The utility of microdosing over the past 5 years

Bibliography

• EMEA, Position Paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper CPMP/SWP/2599, 23 June 2004
   Google Scholar
• Food and Drug Administration US Department of Health and Human Services Guidance for Industry Investigators and Reviewers. Exploratory IND Studies. January 2006
   Google Scholar
• ICH Topic M3 (R2): note for guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95 (July 2008)
   Google Scholar
• Rowland M. Microdosing and the 3Rs, in National Centre for the Replacement, Refinement & Reduction of animals in Research. 2006, NC3Rs: Manchester
   Google Scholar
• Combes RD, Berridge T, Connelly J, et al. Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 2003;19(1):1-11
   PubMed Web of Science ®Google Scholar
• Kimmelman J. Ethics at phase 0: clarifying the issues. J Law Med Ethics 2007;35(4):727-33,514
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003;2(3):233-40
   PubMed Web of Science ®Google Scholar
• Walker DK. The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development. Br J Clin Pharmacol 2004;58(6):601-8
   PubMed Web of Science ®Google Scholar
• Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002;54(3):433-51
   PubMed Web of Science ®Google Scholar
• Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 2004;32(6):603-11
   PubMed Web of Science ®Google Scholar
• Bertino JS Jr, Greenberg HE, Reed MD. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007;47(4):418-22
   PubMed Web of Science ®Google Scholar
• Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007;47(12):1595-6; author reply 1597-8
   PubMed Web of Science ®Google Scholar
• Lappin G, Stevens L. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 2008;4(8):1021-33
   PubMed Web of Science ®Google Scholar
• Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81(1):24-6
   PubMed Web of Science ®Google Scholar
• Eliopoulos H, Giranda R, Carr R, et al. Phase 0 trials: an industry perspective. Clin Cancer Res 2008;14(12):3683-8
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. A review of human phase 0 and microdosing clinical trials following the US food and drug administration exploratory investigational new drug studies guidance. Int J Pharm Med 2006;30(3):159-65
   Google Scholar
• Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999;37(1):1-16
   PubMed Web of Science ®Google Scholar
• Murnick DE, Dogru O, Ilkmen E. Intracavity optogalvanic spectroscopy. An analytical technique for 14C analysis with subattomole sensitivity. Anal Chem 2008;80(13):4820-4
   PubMed Web of Science ®Google Scholar
• Koetz BS, Price PM. Positron Emission Tomography, in Radiotracers in Drug Development, G. Lappin and S. Temple, Editors. 2006, Taylor Francis: Boca Ratton, Florida, USA
   Google Scholar
• Halldin C, Stone-Elander S, Farde L, et al. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 1986;37(10):1039-43
   PubMedGoogle Scholar
• Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008;11(1):104-10
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003;59(5-6):357-66
   PubMed Web of Science ®Google Scholar
• Salehpour M, Possnert G, Bryhni H. Zeptomole sensitivity in biological accelerator mass spectrometry. Anal Biochem 2008. In press
   Google Scholar
• Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal Biochem 2008;378:93-5
   PubMed Web of Science ®Google Scholar
• Lappin G, Garner RC. The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metab Toxicol 2005;1(1):23-32
   PubMedGoogle Scholar
• Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006;34(3):384-8
   PubMed Web of Science ®Google Scholar
• Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther ,2006;80(3):203-15
   PubMed Web of Science ®Google Scholar
• Ni J, Ouyang H, Aiello M, et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 2008;25(7):1572-82
   PubMed Web of Science ®Google Scholar
• Sandhu P, Vogel JS, Rose MJ, et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004;32(11):1254-9
   PubMed Web of Science ®Google Scholar
• Vuong LT, Ruckle JL, Blood AB, et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 2007; DOI:10.1002/jps.21160
   Google Scholar
• Yamane N, Tozuka Z, Sugiyama Y, et al. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007;858(1-2):118-28
   PubMed Web of Science ®Google Scholar
• Madan A, O'Brien Z, Wen J, et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2008. In press
   Google Scholar
• Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl )acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-8
   PubMed Web of Science ®Google Scholar
• Kavanagh F, Dennin IJ. Erythromycin in analytical microbiology. In: Kavanagh F, editor. Academic Press: New York; 1963. p. 289
   Google Scholar
• Lappin G, Rowland M, Garner RC, The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2006;2(3):419-27
   PubMed Web of Science ®Google Scholar
• Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003;92(5):985-4
   PubMed Web of Science ®Google Scholar
• The website of the European Microdosing AMS Partnership Programme, a research project funded by the European Commission under the Framework Programme 6. Available from: www.EUMAPP.com
   Google Scholar